A Phase 1/2, Open-Label, Dose-Escalation Study of ISB 1302 in Subjects With HER2-Positive Metastatic Breast Cancer
Latest Information Update: 04 Feb 2020
At a glance
- Drugs ISB 1302 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd; Ichnos Sciences
- 29 Jan 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 22 Jun 2019 to 15 Feb 2020.
- 15 Oct 2019 According to an Ichnos Sciences media release, data readout from this trial is expected in 2021.
- 29 Aug 2019 Status changed from not yet recruiting to recruiting.